Management of Persistent Urethritis Despite Doxycycline Treatment

Initial Assessment

The Centers for Disease Control and Prevention recommends confirming objective signs of urethritis before initiating further antimicrobial therapy, including the presence of discharge or ≥5 polymorphonuclear leukocytes per high-power field 1, 2
Symptoms alone, without documentation of signs or laboratory evidence of urethral inflammation, are not sufficient basis for re-treatment, as stated by the Centers for Disease Control and Prevention 3
The Centers for Disease Control and Prevention suggests ruling out non-compliance with initial treatment regimen or re-exposure to an untreated sexual partner, which would warrant repeating the initial regimen 2

The Centers for Disease Control and Prevention recommends performing culture or NAAT testing for Trichomonas vaginalis using an intraurethral swab or first-void urine specimen 1
The Centers for Disease Control and Prevention suggests considering testing for tetracycline-resistant Ureaplasma urealyticum, which may cause recurrent urethritis after doxycycline treatment 1, 2

The Centers for Disease Control and Prevention recommends metronidazole 2 g orally in a single dose OR Tinidazole 2 g orally in a single dose for first-line treatment of persistent/recurrent urethritis 1
The Centers for Disease Control and Prevention recommends adding Azithromycin 1 g orally in a single dose (if not used for initial episode) to the first-line treatment regimen 1
For alternative regimens, the Centers for Disease Control and Prevention suggests metronidazole 2 g orally in a single dose PLUS Erythromycin base 500 mg orally four times a day for 7 days OR Erythromycin ethylsuccinate 800 mg orally four times a day for 7 days 3

The Centers for Disease Control and Prevention recommends referring all sexual partners within the preceding 60 days for evaluation and treatment 1
The Centers for Disease Control and Prevention suggests that partners should receive the same treatment regimen as the index patient 2
The Centers for Disease Control and Prevention advises that both patient and partners should abstain from sexual intercourse until 7 days after therapy is initiated, provided symptoms have resolved and partners have been adequately treated 1

The Centers for Disease Control and Prevention recommends that patients should return for evaluation if symptoms persist or recur after completion of therapy 1
The Centers for Disease Control and Prevention suggests that persistence of pain, discomfort, and irritative voiding symptoms beyond 3 months should alert the clinician to the possibility of chronic prostatitis/chronic pelvic pain syndrome 1

The Centers for Disease Control and Prevention recommends that HIV-infected patients with NGU should receive the same treatment regimen as HIV-negative patients 1
The Centers for Disease Control and Prevention notes that urologic examinations usually do not reveal a specific etiology in cases of persistent urethritis 1

The Centers for Disease Control and Prevention warns against treating based on symptoms alone without confirming objective signs of urethritis 1
The Centers for Disease Control and Prevention advises against failing to address possible reinfection from untreated partners 2